Group 1 - The company and its subsidiaries, Suzhou Yifan Pharmaceutical Co., Ltd. and Beijing Yiyi Biopharmaceutical Co., Ltd., have received the "High-tech Enterprise Certificate" from relevant authorities, confirming their status as high-tech enterprises [1] - The recognition of high-tech enterprise status allows both subsidiaries to enjoy a preferential corporate income tax rate of 15% for three consecutive years from 2025 to 2027, following the expiration of their previous certificates [1] - The company has already filed tax returns for 2025 at the 15% rate, indicating that the new recognition will not impact the financial data for 2025 but is expected to have a positive effect on the company's operating performance in subsequent years [1]
证券代码：002019 证券简称：亿帆医药 公告编号：2026-012